Mural oncology reports inducement grants under nasdaq listing rule 5635(c)(4)

Waltham, mass. and dublin, june 04, 2024 (globe newswire) -- mural oncology plc (nasdaq: mura), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that on june 3, the company granted to two newly hired employees (i) non-statutory stock options to purchase an aggregate of 7,995 ordinary shares of the company and (ii) restricted stock units with respect to an aggregate of 4,305 ordinary shares of the company, pursuant to the company's 2024 inducement stock option and incentive plan, each as an inducement material to the new employees entering into employment with the company in accordance with nasdaq listing rule 5635(c)(4).
NDAQ Ratings Summary
NDAQ Quant Ranking